General Toxicity Notes
Blood levels most often the best guide to therapy. Half-life may be prolonged in heart failure or with reduced hepatic blood flow.
Excreted Unchanged %
50-60
Half-Life (Normalesrd) Hours
7/22
Plasma Protein Binding %
50
Volume Of Distribution L/Kg
4-5
Dose For Normal Renal Function
130-160 mg q12h
Adjustment For Renal Failure Method
D, I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% q12h [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% q12h [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
66% q24h [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None
Supplement For Dialysis [Recommendation Level]: Pd
PD: None
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Aronoff G, Brier M, Mayer ML, Barbalas M, Aogaichi K, Sloan R, et al. Bio-availability and kinetics of cibenzoline in patients with normal and impaired renal function. J Clin Pharmacol. 1991; 31: 38-44. [PMID: 2045527] / Harron DW, Brogden RN, Faulds D, Fitton A. Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias. Drugs. 1992; 43: 734-59. [PMID: 1379150] / Massarella JW, Khoo KC, Aogaichi K, Di Persio D, Smith M, Kluger J, et al. Effect of renal impairment on the pharmacokinetics of cibenzoline. Clin Pharmacol Ther. 1988; 43: 317-23. [PMID: 3345622]